Investor Overview

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All clinical candidates were invented internally by Synta scientists using our compound library and discove... More >>

Date Title   07/27/10 Synta Announces STA-9090 Results Published in Journal "Blood" Demonstrating Potent In Vitro and In Vivo Activity in AML - STA-9090 inhibits WT1, a key driver of leukemias - - STA-9090 enhances activity of chemotherapy in leukemia cells - - STA-9090 currently being studied in two AML clinical trials - LEXINGTON, Mass., Jul 27, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results pre-published in the online edition of the journal Blood show that STA-9090 causes degradation of the Wilms' tumor 1 (WT1) protein and its downstream target proteins, c-Myc and Bcl-2, key fac...  07/26/10 Synta Pharmaceuticals to Host Second-Quarter 2010 Conference Call on August 9, 2010 Conference call to be held after market closes LEXINGTON, Mass., Jul 26, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its second-quarter 2010 financial results after the market closes on Monday, August 9, 2010. Management will conduct a conference call at 4:30 p.m. (ET) that day to revie...  06/07/10 Synta Announces Encouraging STA-9090 Clinical Results Presented at ASCO - STA-9090 well-tolerated in Phase 1 solid tumor studies at dose levels up to 216mg/m2 - - Promising single-agent clinical activity observed across multiple tumor types - LEXINGTON, Mass., Jun 07, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting ...